Jim Simons
KYMR icon

Jim Simons’s Kymera Therapeutics KYMR Stock Holding History

Jim Simons’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-143,093
Closed -$4.27M – 3729
2024
Q2 		$4.27M Buy
+143,093
New +$4.95M 0.01% 1411
2022
Q2 		– Sell
-172,800
Closed -$7.31M – 4420
2022
Q1 		$7.31M Buy
172,800
+140,700
+438% +$5.94M 0.01% 1339
2021
Q4 		$2.04M Buy
+32,100
New +$1.87M ﹤0.01% 2127

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jim Simons's KYMR Position: Q3 2024 in Review

Jim Simons sold out of Kymera Therapeutics (KYMR) in Q3 2024, closing a stake of 143,093 shares — an estimated $4.27M sold.

Jim Simons first reported a position in KYMR in Q4 2021 and held it in 3 quarters. The position peaked at $7.31M in Q1 2022. 176 funds tracked by Wall St. Rank hold KYMR as of Q3 2024.

  • Jim Simons reported no remaining Kymera Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jim Simons sold 143,093 Kymera Therapeutics shares in Q3 2024, an estimated $4.27M.
  • Jim Simons first reported a position in Kymera Therapeutics in Q4 2021 and held it in 3 quarters.
  • Jim Simons's Kymera Therapeutics position peaked at $7.31M in Q1 2022.
  • 176 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.